Health
GSK’s Blood Cancer Drug Approved in UK, Paving Return to Market
The GSK headquarters in London.
Photographer: Chris Ratcliffe/BloombergThis article is for subscribers only.
GSK Plc’s blood cancer drug Blenrep has won approval from the UK medicines regulator, opening the door to the return of a treatment that was withdrawn from the market about two years ago.
In a boost for the British drugmaker, the UK is the first country to authorize Blenrep, in combination with other oncology drugs, for some patients with multiple myeloma, an incurable blood cancer, after they have received one previous treatment.